Taken together with our previous finding that patients with breast cancer positive for both receptors had prolonged benefit from 2 years of TAM compared with patients having tumors positive for ER only, our data show that PR positivity tends to increase breast cancer sensitivity to adjuvant TAM [4]. Here, ESR1 is linked to breast carcinoma.